Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.
暂无分享，去创建一个
S. Baker | Ji Young Kim | A. Sparreboom | K. Suszták | Michael S. Balzer | K. Jhaveri | R. Cianciolo | A. Bajwa | Veronika Sander | N. Pabla | J. Prosek | J. Silvaroli | Yuntao Bai | L. Jayne | M. Gandhi | Kevin M. Huang | Bijay Bisunke | Laura A. Jayne | Navjotsingh Pabla